270 related articles for article (PubMed ID: 26490423)
21. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
[TBL] [Abstract][Full Text] [Related]
22. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
Negi SS; Brown P
Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
[TBL] [Abstract][Full Text] [Related]
23. Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription.
Kang J; Kusnadi EP; Ogden AJ; Hicks RJ; Bammert L; Kutay U; Hung S; Sanij E; Hannan RD; Hannan KM; Pearson RB
Oncotarget; 2016 Aug; 7(31):48887-48904. PubMed ID: 27385002
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.
Quin J; Chan KT; Devlin JR; Cameron DP; Diesch J; Cullinane C; Ahern J; Khot A; Hein N; George AJ; Hannan KM; Poortinga G; Sheppard KE; Khanna KK; Johnstone RW; Drygin D; McArthur GA; Pearson RB; Sanij E; Hannan RD
Oncotarget; 2016 Aug; 7(31):49800-49818. PubMed ID: 27391441
[TBL] [Abstract][Full Text] [Related]
25. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
[TBL] [Abstract][Full Text] [Related]
26. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.
Deng C; Lipstein MR; Scotto L; Jirau Serrano XO; Mangone MA; Li S; Vendome J; Hao Y; Xu X; Deng SX; Realubit RB; Tatonetti NP; Karan C; Lentzsch S; Fruman DA; Honig B; Landry DW; O'Connor OA
Blood; 2017 Jan; 129(1):88-99. PubMed ID: 27784673
[TBL] [Abstract][Full Text] [Related]
27. Role of DHX33 in c-Myc-induced cancers.
Fu J; Liu Y; Wang X; Yuan B; Zhang Y
Carcinogenesis; 2017 Jun; 38(6):649-660. PubMed ID: 28498893
[TBL] [Abstract][Full Text] [Related]
28. The aryl hydrocarbon receptor regulates nucleolar activity and protein synthesis in MYC-expressing cells.
Lafita-Navarro MC; Kim M; Borenstein-Auerbach N; Venkateswaran N; Hao YH; Ray R; Brabletz T; Scaglioni PP; Shay JW; Conacci-Sorrell M
Genes Dev; 2018 Oct; 32(19-20):1303-1308. PubMed ID: 30254109
[TBL] [Abstract][Full Text] [Related]
29. Signaling to the ribosome in cancer--It is more than just mTORC1.
Hannan KM; Sanij E; Hein N; Hannan RD; Pearson RB
IUBMB Life; 2011 Feb; 63(2):79-85. PubMed ID: 21360636
[TBL] [Abstract][Full Text] [Related]
30. The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas.
D'Andrea A; Gritti I; Nicoli P; Giorgio M; Doni M; Conti A; Bianchi V; Casoli L; Sabò A; Mironov A; Beznoussenko GV; Amati B
Oncotarget; 2016 Nov; 7(45):72415-72430. PubMed ID: 27635472
[TBL] [Abstract][Full Text] [Related]
31. The Transcription Factor ASCIZ and Its Target DYNLL1 Are Essential for the Development and Expansion of MYC-Driven B Cell Lymphoma.
Wong DM; Li L; Jurado S; King A; Bamford R; Wall M; Walia MK; Kelly GL; Walkley CR; Tarlinton DM; Strasser A; Heierhorst J
Cell Rep; 2016 Feb; 14(6):1488-1499. PubMed ID: 26832406
[TBL] [Abstract][Full Text] [Related]
32. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.
Kim DW; Wu N; Kim YC; Cheng PF; Basom R; Kim D; Dunn CT; Lee AY; Kim K; Lee CS; Singh A; Gazdar AF; Harris CR; Eisenman RN; Park KS; MacPherson D
Genes Dev; 2016 Jun; 30(11):1289-99. PubMed ID: 27298335
[TBL] [Abstract][Full Text] [Related]
33. Aberrant ribosome biogenesis activates c-Myc and ASK1 pathways resulting in p53-dependent G1 arrest.
Kim HD; Kim TS; Kim J
Oncogene; 2011 Jul; 30(30):3317-27. PubMed ID: 21383696
[TBL] [Abstract][Full Text] [Related]
34. Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.
Zhang X; Bi C; Lu T; Zhang W; Yue T; Wang C; Tian T; Zhang X; Huang Y; Lunning M; Hao X; Brown LE; Devine WG; Vose J; Porco JA; Fu K
Leukemia; 2020 Jan; 34(1):138-150. PubMed ID: 31171817
[TBL] [Abstract][Full Text] [Related]
35. Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer.
Wiegering A; Uthe FW; Jamieson T; Ruoss Y; Hüttenrauch M; Küspert M; Pfann C; Nixon C; Herold S; Walz S; Taranets L; Germer CT; Rosenwald A; Sansom OJ; Eilers M
Cancer Discov; 2015 Jul; 5(7):768-781. PubMed ID: 25934076
[TBL] [Abstract][Full Text] [Related]
36. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy.
Duo Y; Yang M; Du Z; Feng C; Xing C; Wu Y; Xie Z; Zhang F; Huang L; Zeng X; Chen H
Acta Biomater; 2018 Oct; 79():317-330. PubMed ID: 30172068
[TBL] [Abstract][Full Text] [Related]
37. Myc as a Regulator of Ribosome Biogenesis and Cell Competition: A Link to Cancer.
Destefanis F; Manara V; Bellosta P
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32516899
[TBL] [Abstract][Full Text] [Related]
38. Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer.
Bursać S; Prodan Y; Pullen N; Bartek J; Volarević S
Trends Cancer; 2021 Jan; 7(1):57-76. PubMed ID: 32948502
[TBL] [Abstract][Full Text] [Related]
39. FoxO3 suppresses Myc-driven lymphomagenesis.
Vandenberg CJ; Motoyama N; Cory S
Cell Death Dis; 2016 Jan; 6(1):e2046. PubMed ID: 26764572
[TBL] [Abstract][Full Text] [Related]
40. Targeting the nucleolus for cancer intervention.
Quin JE; Devlin JR; Cameron D; Hannan KM; Pearson RB; Hannan RD
Biochim Biophys Acta; 2014 Jun; 1842(6):802-16. PubMed ID: 24389329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]